Defining Go And No-Go Disease Areas As An R&D Business
Exploring How Unmet Need Effects Decision-Making And How The Term Has Evolved
Executive Summary
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.
You may also be interested in...
Is Pharma Doing Enough To Enable Access To COVID-19 Vaccines Everywhere?
The race to develop COVID-19 vaccines is intensifying long-standing debate over the ability of lower-income countries to gain affordable access to needed medical treatments. Patient advocates argue that drug makers and wealthy governments are striking deals that place poor countries at a disadvantage. The pharmaceutical industry, however, maintains it is moving as quickly as possible to not only discover safe and effective vaccines, but to enable equitable distribution.
Regulators Seek Solutions To Manufacturing Woes
Over the past few years, frustrating instances of shortages and recalls – particularly generics – have been blamed on inferior quality control at countless suppliers of active pharmaceutical ingredients and finished products, especially those based in India and China.
Understanding The Evolving Medical Cannabis Market
In case you have not noticed, a new gold rush appears to be under way. Buoyed by surging interest in medical cannabis, big and small companies from around the world are racing to take advantage of the potential for the marijuana plant to cure numerous diseases and take its place in the pantheon of pharmaceutical products.
Need a specific report? 1000+ reports available
Buy Reports